KR20190074566A - Composition for skin whitening comprising Cacalia firma extract as effective component - Google Patents

Abstract

The present invention relates to a skin whitening composition containing a Cacalia firma extract as an active ingredient. The Cacalia firma extract of the present invention has an excellent effect of suppressing melanin biosynthesis and tyrosinase activity, and thus can be effectively used as a functional cosmetic for skin whitening, a functional health food capable of preventing or ameliorating skin pigmentation disease, or a therapeutic agent for skin pigmentation disease.

Description

[0001] The present invention relates to a composition for skin whitening comprising an extract of Panax obturator as an active ingredient (Composition for skin whitening comprising Cacalia extract as effective component)

The present invention relates to a cigarette case The present invention relates to a composition for skin whitening comprising an extract of Aspergillus oryzae as an active ingredient and, more particularly, .

From ancient times, white and light skin has been recognized not only as beauty but also as a symbol of health and reputation. Melanocytes in the lower basal layer of the epidermis are made up of melanin by the various stimulants of the skin and sent to the upper layer. When the melanin reaches the stratum corneum, the skin appears black. Factors involved in melanin formation include follicular hormone, progesterone, pigment cell stimulating hormone, sunlight ultraviolet light, stress and genetics.

It is called skin whitening that the unwanted melanin pigment is quickly released and the inherent transparency of the person's skin is regained. The KFDA is registered as a whitening ingredient with mulberry extract, arbutin, ethyl ascorbic ether, soluble licorice extract, ascorbyl glucoside, niacinamide, alpha-bisabolol and ascorbyl tetraisopalmitate. It is whitening cosmetics made with liquids, creams, mask packs and so on.

The extracts of mulberry, arbutin, alpha-bisabolol and the soluble licorice extract inhibit the activation of tyrosinase, an enzyme involved in the production of melanin, and ascorbyl glucoside, ethyl ascorbyl ether and ascorbyl tetraisopalmitate inhibit tyrosinase enzyme Inhibits the oxidation of stimulated tyrosine, and niacinamide inhibits the step of transferring already produced melanin from melanocytes to keratinocytes, thus preventing the final step of melanin entering the skin cells.

Representatives of substances used for medical purposes, not cosmetics, are hydroquinones prescribed as pharmaceuticals. Hydroquinone is mainly used for skin ointment. To buy an ointment containing more than 4% of this substance in Korea, a doctor's prescription must be provided, and 2% can be purchased at a pharmacy without a prescription. Unlike whitening cosmetics, hydroquinone ointment, used for medical purposes, directly destroys melanin-bearing skin cells and helps new skin cells grow.

However, there is a problem that the above-mentioned substances exhibit a tyrosinase inhibitory effect only at a relatively high concentration, or the application range of the product is so narrow that the effect is not maintained for a long time due to a low stability. Hydroquinone has a problem of skin irritation and stability Use in cosmetics is limited.

On the other hand, Cacalia firm is a perennial herbaceous plant belonging to Asteraceae which is a kind of fennel called a big screen or a screening work. It is distributed in forests of deep mountains of Korea and northeastern China, and its height is very high, 1 ~ 2m. The roots are long and rounded with petiole. The diameter is 27 ~ 32㎝, the edge is divided into 11 ~ 15 pieces. The cut pieces are triangular ovate with irregular sawtooth. The flowers bloom in June to August in yellowish white color, and run on the branch of the cone flower with gunshot. The plant has a unique scent, and young plants eat it as herbs. Currently, there are few cases of domestic and foreign researches on the folding screen, and there is little research on the efficacy of folding screens.

Korean Patent Registration No. 1143980 discloses a method for drying a fennel which includes a fennel, but has not been disclosed for a skin whitening composition containing the extract of the fennel extract of the present invention as an active ingredient.

It is an object of the present invention to provide a skin whitening composition containing an extract of Aspergillus oryzae as an active ingredient and to provide a skin whitening composition which is excellent in the effect of suppressing melanin biosynthesis and tyrosinase activity By confirming, the present invention has been completed.

In order to solve the above-mentioned problems, the present invention provides a cosmetic composition for skin whitening comprising an extract of Panax obturator as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing or treating a melanin pigment hyperpigmentation disorder, which comprises an extract of Panax annuus as an active ingredient.

The present invention also provides a health functional food composition for preventing or ameliorating a melanin pigment hyperpigmentation disorder, which comprises an extract of Panax annuus as an active ingredient.

The present invention relates to a cigarette case The present invention relates to a skin whitening composition containing an extract of Panax obtusa extract as an active ingredient, and the extract of Panax annatum extract of the present invention has an excellent effect of inhibiting melanin biosynthesis and tyrosinase activity, Can be used as a functional material for skin whitening.

FIG. 1 shows the results of confirming the cell survival rate according to the concentration of the extract. CON is an untreated negative control group.
FIG. 2 shows the degree of suppression of melanin biosynthesis according to the concentration of the extract of Panax annuus. α-MSH was induced to induce melanin biosynthesis, and arbutin was treated as a positive control.
Fig. 3 shows the results of the inhibitory activity of tyrosinase activity according to the concentration of the extract of Panax annuus. α-MSH was treated to induce melanin biosynthesis, and arbutin was treated as a positive control.

The present invention relates to a cigarette case The present invention relates to a cosmetic composition for whitening skin, which contains, as an active ingredient,

In the cosmetic composition according to one embodiment of the present invention, the solvent of the extract is a lower alcohol of C ₁ to C ₄ , water or a mixture thereof, preferably ethanol, as a solvent.

The extract may contain, but is not limited to, inhibiting the biosynthesis of melanin and inhibiting the activity of tyrosinase.

In the present invention, the skin whitening effect is an effect of improving or preventing glaring skin, spots, freckles and dark circles caused by various factors such as exposure to ultraviolet rays, change in hormone balance, genetic program, etc., Or an effect of maintaining a beautiful skin with a sense of transparency and an effect of reducing the dullness of the skin to increase gloss and tautness. Generally, it is known that the skin, spots, freckles, and dark circles are stimulated by melanocytes due to stimulation by ultraviolet rays or changes in hormone balance, and melanin pigment that is biosynthesized thereby is deposited on the skin. Therefore, if the production of melanin can be inhibited, it is possible to prevent or improve gross skin, spots, freckles and dark circles.

In the cosmetic composition according to one embodiment of the present invention, the skin whitening cosmetic composition may be at least one selected from the group consisting of skin, skin softener, skin toner, lotion, milk lotion, But are not limited to, any one form of cream, hand cream, essence, nutrition essence, pack, cleansing foam, cleansing water, cleansing cream, body lotion, body cleanser, soap and powder. The cosmetic composition comprising each of these formulations may contain various bases and additives necessary for formulation of the formulation, and the kinds and amounts of these ingredients can be easily selected by those skilled in the art.

The cosmetic composition of the present invention may contain, in addition to the active ingredient, at least one skin whitening active ingredient exhibiting the same or similar functions. Skin whitening active ingredients include kojic acid and its derivatives, arbutin, ascorbic acid and its derivatives, hydroquinone and its derivatives, resorcinol, cycloalkanone, methylenedioxyphenylalkanol, 2,7-dinitroindazole or Plant extracts such as mandarin orange extract, rice extract, licorice extract, and the like, but are not limited thereto.

When the formulation of the cosmetic composition of the present invention is a paste, a cream or a gel, an animal fiber, a plant fiber, a wax, a paraffin, a starch, a tragacanth, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Etc. may be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, Propellants such as carbon, propane-butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or an emulsion, a solvent, a solvent or an emulsifier is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspension such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the cosmetic composition of the present invention is an interfacial-active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, acethionate, imidazolinium derivative, methyltaurate, sarcosinate , Fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative or ethoxylated glycerol fatty acid ester.

The cosmetic composition of the present invention may further contain an excipient including a fluorescent substance, a fungicide, a hygroscopic substance, a moisturizer, a fragrance, a fragrance carrier, a protein, a solubilizer, a sugar derivative, a sunscreen, a vitamin, .

The present invention also screens rolls (Cacalia The present invention also relates to a pharmaceutical composition for preventing or treating a melanin pigment hyperpigmentation disease.

As used herein, the term " melanin pigment hyperpigmentation "means darkening or darkening compared to other areas due to excessive increase of melanin in specific areas of the skin or nail. The melanin pigment hyperpigmentation disorder is a hyperpigmentation disorder caused by inflammation caused by freckles, senile spots, liver, spots, brown or black spots, daylight pigmentation, cyanic melasma, hyperpigmentation after drug use, scratches, burns or dermatitis Including but not limited to implantation, deposition or gravidic chloasma, and the like.

The pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier in addition to the active ingredient. Such a carrier is usually used at the time of formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, Calcium carbonate, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals Oils, and the like, but are not limited thereto. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences, 19th ed., 1995.

The appropriate dosage of the pharmaceutical composition according to the present invention may vary depending on such factors as the formulation method, the administration method, the patient's age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, .

The pharmaceutical composition of the present invention may be administered orally or parenterally. In the case of parenteral administration, the composition may be administered topically to the skin, intravenously, subcutaneously, intramuscularly, intraperitoneally, or transdermally. In view of the fact that the pharmaceutical composition of the present invention is applied for the treatment or prevention of a melanin pigment hyperpigmentation disease, it is preferable that the composition is topically applied to the skin.

The concentration of the active ingredient contained in the composition of the present invention may be determined in consideration of the purpose of treatment, the condition of the patient, the period of time required, and the like, and is not limited to a specific range of concentration.

The pharmaceutical composition of the present invention may be manufactured in a unit dosage form by formulating it using a pharmaceutically acceptable carrier or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs Into a capacity container. The formulations may be formulated into any one of the formulations selected from injectables, creams, patches, sprays, ointments, alerts, lotions, liniments, pastes and cataplasms, and may additionally contain dispersing or stabilizing agents have.

The present invention also screens rolls (Cacalia The present invention also relates to a health functional food composition for preventing or ameliorating a melanin pigment hyperpigmentation disease.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is, or may be used together with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient can be suitably used depending on its use purpose (prevention or improvement). Generally, the health functional food composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount of more than the above range.

There is no particular limitation on the kind of the health functional food. Examples of the foods to which the health functional food composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, soups, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

In addition, the health functional food composition of the present invention can be produced as a food, particularly a functional food. The functional food of the present invention includes components that are ordinarily added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of a drink, a natural carbohydrate or a flavoring agent may be included as an additional ingredient in addition to the active ingredient. The natural carbohydrate may be selected from the group consisting of monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, , Xylitol, sorbitol, erythritol, etc.). The flavoring agent may be a natural flavoring agent (e.g., tau Martin, stevia extract, etc.) and a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).

In addition to the above-mentioned health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in beverages, and the like. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected in the range of 0.01 to 0.1 part by weight based on 100 parts by weight of the health functional food composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Examples. It is to be understood by those skilled in the art that these preparations and examples are merely intended to explain the present invention more specifically and that the scope of the present invention is not limited thereto.

Manufacturing example  One. Sides  Preparation of extract

In this experiment, 10% of 70% (v / v) ethanol was added to the ginseng and the mixture was stirred at room temperature for 10 hours. The extracts were then centrifuged, and the supernatant was filtered and concentrated, lyophilized, and stored in a refrigerated room.

Example  One. Sides  Identification of cell viability of extract

(MTT) (3- (4,5-dimeth-ylthiazol-2-yl) -ethanone was prepared by using the method of Mosmann (1983) yl) -2,5-diphenyltetrazolium bromide) analysis.

B16-F10 mouse melanoma cells were cultured in a 96-well plate containing 100 占 퐇 of DMEM medium for 1 day, followed by treatment with a concentration of (50, 100 and 200 占 퐂 / ml) Then, 10 μl of 5 mg / ml MTT solution was added to each well, followed by culturing for 3 hours to induce a reduction reaction. 100 μl of DMSO (dimethyl sulfoxide) solution was added to form purple formazan ) Crystals were completely dissolved. After that, the absorbance was measured at 570 nm using a spectrophotometer, and the relative cell viability was calculated in the group treated with the extract of Panax annuus, based on the survival rate of 100% of the non-treated group. As a result, as shown in Fig. 1, the extracts of Panax annuus according to the concentration of Preparation Example 1 did not significantly affect the cell viability, indicating that there was little cytotoxicity.

Example  2. Sides  Identification of melanin biosynthesis inhibitory effect of extract

Melanoma cells (B16-F10), a mouse melanoma cell, were inoculated on a 12-well plate at a concentration of 1 × 10 ⁵ cells / ml and cultured for 24 hours. Then, α-MSH melanocyte-stimulating hormone was induced to induce melanin biosynthesis, and then arbutin (100 μg / ml) or the extract of Panax annuus (50, 100 and 200 μg / ml) of Preparation Example 1 was treated for 48 hours. After 48 hours, the medium was removed and the cells were washed twice with phosphate buffered saline (PBS), and the adhered cells were centrifuged to obtain a pellet. To the precipitated melanoma cells, 200 1 of 1N NaOH solution containing 10% (v / v) DMSO was added and dissolved at 60 캜 for 1 hour. Absorbance was measured at 405 nm.

As a result, as shown in Fig. 2, the extract of Panax annuus had an effect of inhibiting melanin biosynthesis. In particular, it was confirmed that the effect of inhibiting melanin biosynthesis was excellent when treated with 200 μg / ml of the extract.

Example  3. Sides  Identification of the tyrosinase inhibitory effect of the extract

Tyrosinase activity of α-MSH (melanocyte-stimulating hormone ) after the treatment to induce melanin synthesis buffer 0.1M NaH ₂ PO ₄ (sodium phosphate buffer, pH 6.8) 10mM L-DOPA in 1㎖ (L-3, (50, 100 and 200 / / ml) of arbutin (100 쨉 g / ml) or Preparation Example 1 was added to a mixture of 160 의 of substrate solution and 4 di dihydroxypheny- And Dopa chrome (DOPA chrome) produced in the reaction solution was measured at 475 nm.

As a result, as shown in Fig. 3, the inhibitory effect of tyrosinase was highest when treated with 200 μg / ml of the extract of Panax annuus. In the same manner as in Example 1, Activity inhibitory effect was observed.

From Example 2 and Example 3, it was confirmed that the extract of the present invention of the present invention has an effect of suppressing melanin biosynthesis and inhibiting tyrosinase activity, and can be used as a whitening functional material.

Claims (6)

Cacalia The present invention relates to a cosmetic composition for skin whitening, The cosmetic composition for skin whitening according to claim 1, wherein the solvent of the extract is a C ₁ -C ₄ lower alcohol, water or a mixture thereof. The cosmetic composition for skin whitening according to claim 1, wherein the extract of the sunscreen extract inhibits the biosynthesis of melanin and inhibits the activity of tyrosinase. Cacalia The present invention relates to a pharmaceutical composition for preventing or treating melanin pigment hyperpigmentation diseases, 5. The method of claim 4, wherein the melanin pigment hyperpigmentation disorder is selected from the group consisting of freckles, senile spots, liver, spots, brown or black spots, daylight pigmentation, cyanic melasma, hyperpigmentation after drug use, Characterized in that it is hyperpigmentation or gravidic chloasma after inflammation due to hyperpigmentation caused by the hyperpigmentation of the melanin pigment. Cacalia The present invention relates to a health functional food composition for preventing or ameliorating a melanin pigment hyperpigmentation disease.

Images